ASCO 2026 Data Refinements and Deep Response Analysis in HER2-Positive Metastatic Breast Cancer

Megan Kruse, MD, characterizes the 2026 American Society of Clinical Oncology Annual Meeting (ASCO 2026) presentations as a refinement period for implementing clearly positive phase 3 trial results into daily practice. She emphasizes ongoing challenges in determining appropriate patient selection and optimal sequencing strategies as the field develops greater understanding of patient populations deriving maximum benefit.

The most significant new presentation addressed complete responses, deep responses, and durable responses from DESTINY-Breast09 in first-line metastatic HER2-positive breast cancer. This analysis provides crucial insights for clinicians struggling to identify patients who might succeed with the standard THP regimen (docetaxel, trastuzumab, and pertuzumab) vs those requiring treatment intensification.

Deep response analysis revealed important temporal patterns: Patients achieving partial responses typically demonstrated benefit within the first 2 months, whereas complete responses occurred approximately 8 months into therapy. This timeline challenges traditional approaches of limiting cytotoxic therapy to 6 to 8 cycles based on safety rather than efficacy considerations.

The presentation demonstrated that patients reaching their deepest response required up to 24 months on therapy, challenging preconceptions about shorter up-front treatment durations. Deep responses were defined as 80% to 100% reduction in target lesions, representing maximum shrinkage beyond standard RECIST criteria.

Early-stage safety data addressed radiation pneumonitis and interstitial lung disease (ILD) risks for patients receiving adjuvant fam-trastuzumab deruxtecan-nxki (T-DXd). Overall ILD rates were 14% to 15% in the curative-intent population, higher than neoadjuvant rates (4%-5%) but manageable with appropriate monitoring. Concurrent radiation therapy did not meaningfully increase these rates.

Risk factors included Japanese ethnicity (consistent with previous T-DXd experience) and moderate renal impairment. These findings inform patient selection and monitoring strategies, particularly in curative-intent settings where alternative effective treatments remain available.